At the extreme of the clinical spectrum, if tumor relapse after curative surgery occurs in a single distant site and ERα− to ERα+ conversion is detected, first-line ET plus/minus CDK 4/6 inhibitors should be the preferred treatment option. Here, ESR1 is linked to neoplasm.